New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT06460961
Summary
This early-stage study is testing the safety and initial effectiveness of a new drug called MK-6837, given alone and in combination with an existing immunotherapy (pembrolizumab). It involves 168 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and understand the side effects before testing if it helps control cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM METASTASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atlantic Health System Morristown Medical Center ( Site 4001)
Morristown, New Jersey, 07960, United States
-
Princess Margaret Cancer Centre ( Site 2001)
Toronto, Ontario, M5G 2M9, Canada
-
Providence Portland Medical Center ( Site 4002)
Portland, Oregon, 97213, United States
-
Sheba Medical Center-ONCOLOGY ( Site 3001)
Ramat Gan, 5265601, Israel
-
South Texas Accelerated Research Therapeutics (START) ( Site 4003)
San Antonio, Texas, 78229, United States
-
The Alfred Hospital ( Site 1001)
Melbourne, Victoria, 3004, Australia
-
Westmead Hospital ( Site 1002)
Westmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.